4 Analysts Assess Insulet: What You Need To Know
Portfolio Pulse from Benzinga Insights
Four analysts have recently updated their ratings on Insulet (NASDAQ:PODD), showing a mix of bullish and indifferent stances, with three somewhat bullish and one indifferent rating in the last 30 days. The average 12-month price target for Insulet is now $217.00, with a high estimate of $230.00 and a low estimate of $200.00, marking a slight decrease of 0.46% in the average price target. Insulet's financial performance includes a revenue growth rate of 37.9%, a net margin of 20.26%, an ROE of 15.42%, and an ROA of 4.09%, indicating strong profitability and financial health despite a high debt-to-equity ratio of 1.93.
May 07, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Insulet has received mixed analyst ratings, with a slight decrease in the average 12-month price target. The company's strong financial performance, including significant revenue growth and profitability, positions it well in the market despite a high debt-to-equity ratio.
The mixed analyst ratings with a slight decrease in the price target suggest caution, but Insulet's strong financial performance, including high revenue growth and profitability, indicates a solid foundation that could drive positive short-term stock performance. The high debt-to-equity ratio is a concern but seems manageable given the company's overall financial health.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100